Filter by

  • Publication Year
  • Availability
  • Attachment
  • Collection Type
    See More
  • General Material Designation
    See More
  • Location
    See More
  • Language
Found 6 from your keywords: subject="Chronic Kidney Diseas...
cover
Ketoanalogue-Supplemented Vegetarian Very Low–Protein Diet and CKD Progression
Comment Share
Garneata L

Dietary protein restriction may improve determinants of CKD progression. However, the extent of improvement and effect of ketoanalogue supplementation are unclear. We conducted a prospective, randomized, controlled trial of safety and efficacy of ketoanalogue–supplemented vegetarian very low–protein diet (KD) compared with conventional low–protein diet (LPD). Primary end point was RRT ini…

Edition
-
ISBN/ISSN
-
Collation
-
Series Title
-
Call Number
-
cover
Effects of febuxostat on renal function in patients with chronic kidney disea…
Comment Share
Lin TC

Hyperuricemia has been proven to be an independent risk factor for chronic kidney disease (CKD). However, the role of hyperuricemia in the progression of CKD remains unclear. Thus, we performed a systematic review and metaanalysis to evaluate the efficacy and safety of febuxostat, a first line urate-lowering agent, in CKD patients with hyperuricemia

Edition
-
ISBN/ISSN
-
Collation
-
Series Title
-
Call Number
-
cover
Renal safety and urate-lowering efficacy of febuxostat in gout patients with …
Comment Share
Kim SH

The safety and efficacy of febuxostat in patients with stage 4–5 chronic kidney disease (CKD) are still unclear owing to a lack of studies in these patients. Therefore, we aimed to evaluate the effect of febuxostat on renal function, general safety, and efficacy in gout patients with stage 4–5 CKD

Edition
-
ISBN/ISSN
-
Collation
-
Series Title
-
Call Number
-
cover
Use of darbepoetin alfa in the treatment of anaemia of chronic kidney disease…
Comment Share
Carrera F

The introduction of erythropoiesis-stimulating agents (ESAs) into everyday clinical practice has greatly improved the care of patients with chronic kidney disease. ESAs have reduced the need for blood transfusions, improved survival, decreased cardiovascular complications and enhanced patient quality of life. The longer acting ESA, darbepoetin alfa (AranespR ), which can be administered less fr…

Edition
-
ISBN/ISSN
-
Collation
-
Series Title
-
Call Number
-
cover
Types of erythropoiesis-stimulating agents and risk of end-stage kidney disea…
Comment Share
Minutolo R

Despite the widespread use of erythropoiesisstimulating agents (ESAs) to treat anaemia, the risk of adverse outcomes associated with the use of different types of ESAs in non-dialysis chronic kidney disease (CKD) is poorly investigated

Edition
-
ISBN/ISSN
-
Collation
-
Series Title
-
Call Number
-
cover
Effects of candesartan and amlodipine on cardiovascular events in hypertensiv…
Comment Share
Saruta T

We examined the effects of candesartan and amlodipine on cardiovascular events in hypertensive patients with chronic kidney disease (CKD) using the data from the Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) trial. CKD was defined as proteinuria and/or decreased GFR (o60 ml per min per 1.73m2) at enrollment. Among 2720 subjects with CKD, there were 1376 and 1344 patients…

Edition
-
ISBN/ISSN
-
Collation
-
Series Title
-
Call Number
-